The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Adverse event data will be covered in Adverse events section.
BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
Matching Placebo tid orally for 16 weeks
Corrientes, Argentina